日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario

评估 COVID-19 对意大利肺癌患者诊断治疗路径延迟的影响(COVID-DELAY 研究):真实世界情景下的病例数减少和分期升高

Cantini, L; Mentrasti, G; Russo, G L; Signorelli, D; Pasello, G; Rijavec, E; Russano, M; Antonuzzo, L; Rocco, D; Giusti, R; Adamo, V; Genova, C; Tuzi, A; Morabito, A; Gori, S; Verde, N La; Chiari, R; Cortellini, A; Cognigni, V; Pecci, F; Indini, A; De Toma, A; Zattarin, E; Oresti, S; Pizzutilo, E G; Frega, S; Erbetta, E; Galletti, A; Citarella, F; Fancelli, S; Caliman, E; Della Gravara, L; Malapelle, U; Filetti, M; Piras, M; Toscano, G; Zullo, L; De Tursi, M; Di Marino, P; D'Emilio, V; Cona, M S; Guida, A; Caglio, A; Salerno, F; Spinelli, G; Bennati, C; Morgillo, F; Russo, A; Dellepiane, C; Vallini, I; Sforza, V; Inno, A; Rastelli, F; Tassi, V; Nicolardi, L; Pensieri, V; Emili, R; Roca, E; Migliore, A; Galassi, T; Rocchi, M L Bruno; Berardi, R

Erratum to 'Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario': [ESMO Open Volume 7, Issue 2, April 2022, 100406]

对“COVID-19 对意大利肺癌患者诊断治疗路径延迟的影响评估(COVID-DELAY 研究):真实世界场景中病例数减少、分期更高”的勘误:[ESMO Open 第 7 卷,第 2 期,2022 年 4 月,100406]

Cantini, L; Mentrasti, G; Lo Russo, G; Signorelli, D; Pasello, G; Rijavec, E; Russano, M; Antonuzzo, L; Rocco, D; Giusti, R; Adamo, V; Genova, C; Tuzi, A; Morabito, A; Gori, S; La Verde, N; Chiari, R; Cortellini, A; Cognigni, V; Pecci, F; Indini, A; De Toma, A; Zattarin, E; Oresti, S; Pizzutilo, E G; Frega, S; Erbetta, E; Galletti, A; Citarella, F; Fancelli, S; Caliman, E; Della Gravara, L; Malapelle, U; Filetti, M; Piras, M; Toscano, G; Zullo, L; De Tursi, M; Di Marino, P; D'Emilio, V; Cona, M S; Guida, A; Caglio, A; Salerno, F; Spinelli, G P; Bennati, C; Morgillo, F; Russo, A; Dellepiane, C; Vallini, I; Sforza, V; Inno, A; Rastelli, F; Tassi, V; Nicolardi, L; Pensieri, M V; Emili, R; Roca, E; Migliore, A; Galassi, T; Rocchi, M B L; Berardi, R

P09.15 Severity of Lung Cancer Disease in Hospitalized Patients During COVID-19

P09.15 COVID-19 期间住院肺癌患者的病情严重程度

Aredo, Jacqueline V; Wakelee, Heather A; Han, Summer S; Cantini, L; Mentrasti, G; Siena, S; Pasello, G; Galetti, A; Caliman, E; Rocco, D; Adamo, V; Genova, C; Morabito, A; Gori, S; Rijavec, E; Chiari, R; Oldani, S; Caglio, A; De Tursi, M; Cortellini, A; Morgillo, F; Bennati, C; Guida, A; Spinelli, GP; Emili, R; Roca, E; Indini, A; De Toma, A; Vallini, I; D'Emilio, V; Cognigni, V; Pecci, F; Migliore, A; Della Gravara, L; Frega, S; Zullo, L; Zattarin, E; Citarella, F; Russo, A; Fancelli, S; Oresti, S; Berardi, R; Smeltzer, M; Bunn, B; Choi, YS; Coate, L; Corona-Cruz, J; Drilon, A; Duma, N; Edelman, M; Fidler, MJ; Gadgeel, S; Goto, Y; Herbst, R; Hesdorffer, M; Higgins, K; Labdi, B; Leal, T; Liu, S; Mazotti, J; Novello, S; Patel, S; Popat, S; Ramirez, R; Reckamp, K; Reguart, N; Soo, R; Tan, A; Wolf, J; Yano, S; Stiles, B; Baird, A; Fernández-Mañas, L; Gorría, T; Auclin, E; Reyes, R; Teixidó, C; Marco-Hernández, J; Padrosa, J; De Herreros, M García; Pesántez, D; Martínez, D; Mollà, M; Vollmer, I; Marrades, R; Guirao, A; Prat, A; Viñolas, N; Mezquita, L; Reguart, N

MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study

基于microRNA的特征谱影响卵巢癌的临床进程和生物学:一项miRNA组学研究

Krasniqi, E; Sacconi, A; Marinelli, D; Pizzuti, L; Mazzotta, M; Sergi, D; Capomolla, E; Donzelli, S; Carosi, M; Bagnato, A; Gamucci, T; Tomao, S; Natoli, C; Marchetti, P; Grassadonia, A; Tinari, N; De Tursi, M; Vizza, E; Ciliberto, G; Landi, L; Cappuzzo, F; Barba, M; Blandino, G; Vici, P

Corrigendum to 'The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer': [ESMO Open Volume 6, Issue 2, April 2021, 100078]

对“肺免疫肿瘤预后评分(LIPS-3):接受一线帕博利珠单抗治疗的PD-L1 ≥ 50%晚期非小细胞肺癌患者的预后分类”的更正:[ESMO Open 第6卷,第2期,2021年4月,100078]

Banna, G L; Cortellini, A; Cortinovis, D L; Tiseo, M; Aerts, J G J V; Barbieri, F; Giusti, R; Bria, E; Grossi, F; Pizzutilo, P; Berardi, R; Morabito, A; Genova, C; Mazzoni, F; Di Noia, V; Signorelli, D; Gelibter, A; Macerelli, M; Rastelli, F; Chiari, R; Rocco, D; Gori, S; De Tursi, M; Di Marino, P; Mansueto, G; Zoratto, F; Filetti, M; Montrone, M; Citarella, F; Marco, R; Cantini, L; Nigro, O; D'Argento, E; Buti, S; Minuti, G; Landi, L; Guaitoli, G; Lo Russo, G; De Toma, A; Donisi, C; Friedlaender, A; De Giglio, A; Metro, G; Porzio, G; Ficorella, C; Addeo, A

The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer

肺免疫肿瘤预后评分(LIPS-3):对接受一线帕博利珠单抗治疗的PD-L1≥50%晚期非小细胞肺癌患者进行预后分类

Banna, G L; Cortellini, A; Cortinovis, D L; Tiseo, M; Aerts, J G J V; Barbieri, F; Giusti, R; Bria, E; Grossi, F; Pizzutilo, P; Berardi, R; Morabito, A; Genova, C; Mazzoni, F; Di Noia, V; Signorelli, D; Gelibter, A; Macerelli, M; Rastelli, F; Chiari, R; Rocco, D; Gori, S; De Tursi, M; Di Marino, P; Mansueto, G; Zoratto, F; Filetti, M; Montrone, M; Citarella, F; Marco, R; Cantini, L; Nigro, O; D'Argento, E; Buti, S; Minuti, G; Landi, L; Guaitoli, G; Lo Russo, G; De Toma, A; Donisi, C; Friedlaender, A; De Giglio, A; Metro, G; Porzio, G; Ficorella, C; Addeo, A

OA01.02 Impact of COVID-19 Outbreak on Lung Cancer Diagnosis and Continuum of Care: Data From an Italian Multicenter Study

OA01.02 COVID-19疫情对肺癌诊断和持续治疗的影响:来自一项意大利多中心研究的数据

Mizuno, Yuki; Shimizu-Furusawa, Hana; Konishi, Shoko; Inaoka, Tsukasa; Ahmad, Sk Akhtar; Sekiyama, Makiko; Abdoellah, Oekan S; Gunawan, Budhi; Parajuli, Rajendra Prasad; Ikemoto, Yukio; Lam, Tran Dinh; Watanabe, Chiho; Umezaki, Masahiro; Cantini, L; Mentrasti, G; Siena, S; Pasello, G; Galetti, A; Caliman, E; Rocco, D; Adamo, V; Genova, C; Morabito, A; Gori, S; Rijavec, E; Chiari, R; Oldani, S; Caglio, A; De Tursi, M; Cortellini, A; Morgillo, F; Bennati, C; Guida, A; Spinelli, GP; Emili, R; Roca, E; Indini, A; De Toma, A; Vallini, I; D'Emilio, V; Cognigni, V; Pecci, F; Migliore, A; Della Gravara, L; Frega, S; Zullo, L; Zattarin, E; Citarella, F; Russo, A; Fancelli, S; Oresti, S; Berardi, R

Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation"

关于“循环癌症干细胞衍生的细胞外囊泡作为临床结果评估的新型生物标志物”的更正

Brocco, D; Lanuti, P; Simeone, P; Bologna, G; Pieragostino, D; Cufaro, M C; Graziano, V; Peri, M; Di Marino, P; De Tursi, M; Grassadonia, A; Rapposelli, I G; Pierdomenico, L; Ercolino, E; Ciccocioppo, F; Del Boccio, P; Marchisio, M; Natoli, C; Miscia, S; Tinari, N

Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation.

循环癌干细胞衍生的细胞外囊泡作为临床结果评估的新型生物标志物

Brocco D, Lanuti P, Simeone P, Bologna G, Pieragostino D, Cufaro M C, Graziano V, Peri M, Di Marino P, De Tursi M, Grassadonia A, Rapposelli I G, Pierdomenico L, Ercolino E, Ciccocioppo F, Del Boccio P, Marchisio M, Natoli C, Miscia S, Tinari N